Before IND Know: How To Overcome Early Development Challenges Before They Impact Your Program

The journey from lead candidate selection to clinical development carries inherent risks that can jeopardize a program's timeline and budget. Technical obstacles like poor manufacturability, low expression levels, product quality variances, and immunogenicity risks frequently surface during these initial stages. Left unaddressed, these issues cause expensive delays, forced process re-engineering, and diminished confidence from investors and partners.

Proactively evaluating developability, cell line and vector design, expression optimization, product quality, and immunosafety yields critical early data. Identifying early warning signs through targeted characterization allows drug developers to make data-driven candidate selections and resolve technical vulnerabilities before IND-enabling activities begin. Real-world applications demonstrate that early-stage de-risking strengthens the overall development strategy and streamlines the transition into clinical trials.

Access the full webinar to explore practical strategies for overcoming early development challenges.